Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 10
Submit an article Journal homepage
65
Views
3
CrossRef citations to date
0
Altmetric
Review

Modern antiplatelet agents in coronary artery disease

Rachel F Power Department of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland; Department of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland
,
Brian G Hynes Section of Interventional Cardiology and Vascular Medicine, Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA; Section of Interventional Cardiology and Vascular Medicine, Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA
,
Darragh Moran Department of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland; Department of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland
,
Hatim Yagoub Department of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland; Department of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland
,
Gary Kiernan Department of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland; Department of Interventional Cardiology, Cork University Hospital, University College Cork School of Medicine, Cork, Ireland
,
Nicholas J Ruggiero Division of Interventional Cardiology, Thomas Jefferson Memorial Hospital, Philadelphia, PA, USA; Division of Interventional Cardiology, Thomas Jefferson Memorial Hospital, Philadelphia, PA, USA
&
Thomas J Kiernan Department of Interventional Cardiology, Limerick Regional Hospital, Graduate Entry Medical School (GEMS), Faculty of Education & Health Sciences, University of Limerick, Ireland. [email protected]; Department of Interventional Cardiology, Limerick Regional Hospital, Graduate Entry Medical School (GEMS), Faculty of Education & Health Sciences, University of Limerick, Ireland. [email protected]
 show all
Pages 1261-1272 | Published online: 10 Jan 2014

References

  • Gent M, Beaumont D, Blanchard J et al.; CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038), 1329–1339 (1996).
  • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
  • Gibson CM, Ly HQ, Murphy SA et al.; TIMI Study Group. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28). Am. J. Cardiol. 98(6), 761–763 (2006).
  • Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur. Heart. J. 30, 1964–1977 (2009).
  • Hanson SR, Harker LA, Bjornsson TD. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J. Clin. Invest. 75(5), 1591–1599 (1985).
  • Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N. Engl. J. Med. 296(10), 525–529 (1977).
  • Loew D, Vinazzer H. Dose-dependent influence of acetylsalicyclic acid on platelet functions and plasmatic coagulation factors. Haemostasis 5(4), 239–249 (1976).
  • Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 37(8), 2153–2158 (2006).
  • Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 115(16), 2196–2207 (2007).
  • Maree AO, Curtin RJ, Dooley M et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J. Am. Coll. Cardiol. 46(7), 1258–1263 (2005).
  • Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 308(6921), 81–106 (1994).
  • Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329), 71–86 (2002).
  • Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol. 43(6), 1122–1126 (2004).
  • Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167(15), 1593–1599 (2007).
  • Bhatt DL, Steg PG, Ohman EM et al.; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295(2), 180–189 (2006).
  • Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol. 50(7), e1–e157 (2007).
  • Herbert JF, Vallee DE. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc. Drug Rev. 11, 180–198 (1993).
  • Hochholzer W, Trenk D, Frundi D et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111(20), 2560–2564 (2005).
  • Montalescot G, Sideris G, Meuleman C et al.; ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48(5), 931–938 (2006).
  • Sabatine MS, Cannon CP, Gibson CM et al.; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)–Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294(10), 1224–1232 (2005).
  • Steinhubl SR, Berger PB, Mann JT 3rd et al.; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411–2420 (2002).
  • Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 100(15), 1667–1672 (1999).
  • Hulot JS, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7), 2244–2247 (2006).
  • Shuldiner AR, O’Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8), 849–857 (2009).
  • Luo HR, Poland RE, Lin KM, Wan YJ. Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin. Pharmacol. Ther. 80(1), 33–40 (2006).
  • Wiviott SD, Braunwald E, McCabe CH et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
  • Fork FT, Lafolie P, Tóth E, Lindgärde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand. J. Gastroenterol. 35(5), 464–469 (2000).
  • Tantry US, Kereiakes DJ, Gurbel PA. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc. Interv. 4(4), 365–380 (2011).
  • Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N. Engl. J. Med. 352(3), 238–244 (2005).
  • Bhatt DL, Scheiman J, Abraham NS et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 52(18), 1502–1517 (2008).
  • Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51(3), 256–260 (2008).
  • Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 157(1), 148.e1–148.e5 (2009).
  • O’Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374(9694), 989–997 (2009).
  • Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin. Thromb. Hemost. 25(Suppl. 2), 15–19 (1999).
  • Eikelboom JW, Hirsh J. Bleeding and management of bleeding. Eur. Heart J. 8, G38–G45 (2006).
  • Picker SM, Kaleta T, Hekmat K, Kampe S, Gathof BS. Antiplatelet therapy preceding coronary artery surgery: implications for bleeding, transfusion requirements and outcome. Eur. J. Anaesthesiol. 24(4), 332–339 (2007).
  • Tcheng JE, Ellis SG, George BS et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90(4), 1757–1764 (1994).
  • Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349(9063), 1429–1435 (1997).
  • Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N. Engl. J. Med. 339(7), 436–443 (1998).
  • Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am. J. Cardiol. 89(5), 647–650 (2002).
  • Simoons ML; GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 357(9272), 1915–1924 (2001).
  • Kastrati A, Mehilli J, Neumann FJ et al.; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 295(13), 1531–1538 (2006).
  • Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 359(9302), 189–198 (2002).
  • Winchester DE, Wen X, Brearley WD, Park KE, Anderson RD, Bavry AA. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines. J. Am. Coll. Cardiol. 57(10), 1190–1199 (2011).
  • Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N. Engl. J. Med. 330(14), 956–961 (1994).
  • Hamm CW, Heeschen C, Goldmann B et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N. Engl. J. Med. 340(21), 1623–1629 (1999).
  • Giugliano RP, White JA, Bode C et al.; EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N. Engl. J. Med. 360(21), 2176–2190 (2009).
  • Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 123(18), 2022–2060 (2011).
  • Kushner FG, Hand M, Smith SC Jr et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120(22), 2271–2306 (2009).
  • Mehilli J, Kastrati A, Schulz S et al.; Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119(14), 1933–1940 (2009).
  • Valgimigli M, Campo G, Percoco G et al.; Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 299(15), 1788–1799 (2008).
  • Van’t Hof AW, Ten Berg J, Heestermans T et al.; Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 372(9638), 537–546 (2008).
  • Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc. Drug Rev. 25(4), 357–374 (2007).
  • Niitsu Y, Jakubowski JA, Sugidachi A, Asai F. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin. Thromb. Hemost. 31(2), 184–194 (2005).
  • Brandt JT, Payne CD, Wiviott SD et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153(1), 66.e9–66.16 (2007).
  • Small DS, Farid NA, Li YG et al. Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease. J. Clin. Pharm. Ther. 34(5), 575–583 (2009).
  • Bonello L, Pansieri M, Mancini J et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J. Am. Coll. Cardiol. 58(5), 467–473 (2011).
  • Payne CD, Li YG, Small DS et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J. Cardiovasc. Pharmacol. 50(5), 555–562 (2007).
  • Jernberg T, Payne CD, Winters KJ et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27(10), 1166–1173 (2006).
  • Unger EF. Weighing benefits and risks – the FDA’s review of prasugrel. N. Engl. J. Med. 361(10), 942–945 (2009).
  • Wiviott SD, Trenk D, Frelinger AL et al.; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116(25), 2923–2932 (2007).
  • Montalescot G, Sideris G, Cohen R et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb. Haemost. 103(1), 213–223 (2010).
  • Mehta SR, Tanguay JF, Eikelboom JW et al.; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376(9748), 1233–1243 (2010).
  • Angiolillo DJ, Saucedo JF, Deraad R et al.; SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J. Am. Coll. Cardiol. 56(13), 1017–1023 (2010).
  • Storey RF, Husted S, Harrington RA et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 50(19), 1852–1856 (2007).
  • Bjorkman JA, Kirk I, van Giezen JJ. AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion (abstract 245). Circulation 116, 28 (2007).
  • Peters G, Robbie G. Single-dose pharmacokinetics and pharmacodynamics of AZD6140 – an oral reversible ADP receptor antagonist (abstract). Haematologica 989(Suppl. 7), 14 (2004).
  • Anderson SD, Shah NK, Yim J, Epstein BJ. Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. Ann. Pharmacother. 44(3), 524–537 (2010).
  • Peters G, Buter K, Winter HE, et al. Multiple dose pharmacokinetics and pharmacodynamics of the reversible, orally active ADP receptor antagonist AZD6140 (abstract P4556). Eur. Heart J. 27(Suppl. 1), 758 (2006).
  • Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27(9), 1038–1047 (2006).
  • Cannon CP, Husted S, Harrington RA et al.; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol. 50(19), 1844–1851 (2007).
  • Serebruany VL, Stebbing J, Atar D. Dyspnoea after antiplatelet agents: the AZD6140 controversy. Int. J. Clin. Pract. 61(3), 529–533 (2007).
  • Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25), 2577–2585 (2009).
  • Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
  • Cannon CP, Harrington RA, James S et al.; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375(9711), 283–293 (2010).
  • Wallentin L, James S, Storey RF et al. PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749), 1320–1328 (2010).
  • Jacobsson F, Swahn E, Wallentin L, Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin. Ther. 24(5), 752–765 (2002).
  • Wang K, Zhou X, Zhou Z et al. Sustained coronary artery recanalization with adjunctive infusion of a novel P2T-receptor antagonist AR-C69931 in a canine model. J. Am. Coll. Cardiol. 35, 281A–2A (2000).
  • Greenbaum AB, Ohman EM, Gibson CM et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am. Heart J. 154(4), 702–709 (2007).
  • Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 13(7), 407–413 (2002).
  • Greenbaum AB, Grines CL, Bittl JA et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, Phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J. 151(3), 689.e1–689.e10 (2006).
  • Harrington RA, Stone GW, McNulty S et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med. 361(24), 2318–2329 (2009).
  • Bhatt DL, Lincoff AM, Gibson CM et al.; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med. 361(24), 2330–2341 (2009).
  • Lieu HD, Andre P, Leese PT et al. Initial intravenous experience with PRT060128 (PRT128), an orally-available, direct-acting, and reversible P2y12 inhibitor. J. Thromb Haemost. 5(Suppl. 1), 292 (2007).
  • Gurbel PA, Bliden KP, Antonino MJ et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J. Thromb. Haemost. 8(1), 43–53 (2010).
  • Berger JS, Roe MT, Gibson CM et al. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am. Heart J. 158(6), 998–1004.e1 (2009).
  • Leonardi S, Rao SV, Harrington RA et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am. Heart J. 160, 65–72 (2010).
  • Derian CK, Damiano BP, D’Andrea MR, Andrade-Gordon P. Thrombin regulation of cell function through protease-activated receptors: implications for therapeutic intervention. Biochemistry (Mosco) 67, 56–64 (2002).
  • Andrade-Gordon P, Derian CK, Maryanoff BE et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J. Pharmacol. Exp. Ther. 298(1), 34–42 (2001).
  • Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Proteinase-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. 103, 879–887 (1999).
  • Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3(8), 1800–1814 (2005).
  • Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc. Natl Acad. Sci. U.S.A. 104(1), 288–292 (2007).
  • Derian CK, Damiano BP, Addo MF et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J. Pharmacol. Exp. Ther. 304(2), 855–861 (2003).
  • Kato Y, Kita Y, Hirasawa-Taniyama Y et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur. J. Pharmacol. 473(2–3), 163–169 (2003).
  • Hildemann SK, Bode C. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1. Hamostaseologie. 29(4), 349–355 (2009).
  • Chackalamannil S, Wang Y, Greenlee WJ et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J. Med. Chem. 51(11), 3061–3064 (2008).
  • Chintala M, Vemulapalli S, Kurowski S, et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Arterioscler. Thromb Vasc. Biol. 28, e138–e139 abstract P579 (2008).
  • Becker RC, Moliterno DJ, Jennings LK et al. TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled Phase II study. Lancet 373(9667), 919–928 (2009).
  • Goto S, Yamaguchi T, Ikeda Y, Kato K, Yamaguchi H, Jensen P. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J. Atheroscler. ThCmb. 17(2), 156–164 (2010).
  • Shinohara Y, Goto S, Shimizu K et al. A Phase II safety study of novel antiplatelet agent, SCH 530348, in Japanese patients with prior ischemic stroke. Int. J. Stroke 3(Suppl. 1) 139 abstract PO01-193 (2008).
  • Tricoci P, Huang Z, Held C et al. TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N. Engl. J. Med. 366(1), 20–33 (2012).
  • Morrow DA, Braunwald E, Bonaca MP et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366(15), 1404–1413 (2012).
  • Chackalamannil S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J. Med. Chem. 49(18), 5389–5403 (2006).
  • Kogushi M, Yokohama H, Kitamura S, et al. Effects of E5555, a protease-activated receptor-1 antagonist, on the inflammatory markers in vitro. J. Thromb Haemost 5(Suppl. 2) Abstract P-M-059 (2007).
  • Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL; J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur. Heart J. 31(21), 2601–2613 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.